» Articles » PMID: 8322930

Parathyroid Hormone Increases Cytosolic Calcium Concentration in Adult Rat Cardiac Myocytes

Overview
Journal Am J Physiol
Specialty Physiology
Date 1993 Jun 1
PMID 8322930
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The heart is a target organ for parathyroid hormone (PTH), and the action of this hormone on the myocardium may be mediated through the ability of PTH to increase cytosolic calcium ([Ca2+]i) in the myocardial cells. However, direct evidence for such an effect of PTH is lacking, and the mechanism(s) through which the hormone can potentially exert such an effect have not been elucidated. In the present study these questions were examined using cardiac myocytes isolated from adult rats. Both PTH-(1-34) and PTH-(1-84) produced a dose-dependent increase in [Ca2+]i of myocytes, but the effect of the latter was significantly (P < 0.01) greater than the former. This action of PTH was abolished by the inactivation of the hormone, the use of a PTH antagonist, or by verapamil. The G protein activator, guanosine 5'-O-(3-thiothriphosphate) (GTP gamma S), mimicked the effect of PTH, whereas pertussis toxin, the G protein inhibitor, guanosine 5'-O-(2-thiodiphosphate) (GDP beta S), or ryanodine significantly reduced the PTH-induced rise in [Ca2+]i. Dibutyryl- and 8-bromoadenosine-3',5'-cyclic monophosphate, forskolin, 12-O-tetradecanoylphorbol 13-acetate, and staurosporine did not increase [Ca2+]i in myocytes, and staurosporine did not alter the PTH-induced rise in [Ca2+]i. BAY K 8644 augmented the effect of PTH on [Ca2+]i. These data demonstrate that 1) PTH increases [Ca2+]i of cardiac myocytes, 2) this action is receptor mediated and is produced by activation of the L-type calcium channels following stimulation of G protein(s), and 3) the rise in [Ca2+]i is due to both augmented entry of calcium into the myocytes and mobilization of calcium from sarcoplasmic reticulum by a calcium-induced calcium release mechanism.

Citing Articles

Vitamin D-Parathyroid Hormone-Fibroblast Growth Factor 23 Axis and Cardiac Remodeling.

Deng C, Wu Y Am J Cardiovasc Drugs. 2024; 25(1):25-36.

PMID: 39392562 DOI: 10.1007/s40256-024-00688-8.


Phosphate in Cardiovascular Disease: From New Insights Into Molecular Mechanisms to Clinical Implications.

Turner M, Beck L, Hill Gallant K, Chen Y, Moe O, Kuro-O M Arterioscler Thromb Vasc Biol. 2024; 44(3):584-602.

PMID: 38205639 PMC: 10922848. DOI: 10.1161/ATVBAHA.123.319198.


Effects of Cinacalcet on Post-transplantation Hypercalcemia and Hyperparathyroidism in Adult Kidney Transplant Patients: A Single-Center Experience.

Alpay N, Yildiz A Cureus. 2023; 15(3):e36248.

PMID: 37069889 PMC: 10105616. DOI: 10.7759/cureus.36248.


Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.

McCarty M Int J Mol Sci. 2021; 22(7).

PMID: 33805039 PMC: 8037104. DOI: 10.3390/ijms22073321.


Primary hyperparathyroidism and recurrent ventricular tachyarrhythmia in a patient with novel variant but without structural heart disease.

Pedersen C, Rolighed L, Harslof T, Jensen H, Nielsen J Clin Case Rep. 2019; 7(10):1907-1912.

PMID: 31624606 PMC: 6787842. DOI: 10.1002/ccr3.2363.